The Latest Cardiac and Vascular News
Promotes John Panton to Chief Quality Officer VANCOUVER and MINNEAPOLIS, MN, May 07, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today reported […]
Pharmaceutical expert and Chairman of PTC Therapeutics joins other biotech leaders as Independent Director Westport, CT, May 07, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) today appointed Mr. Michael Schmertzler to the Board of Directors of its majority-owned subsidiary ViralClear Pharmaceuticals, Inc. Mr. Schmertzler […]
SAN FRANCISCO, May 07, 2020 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three months ended March 31, 2020. First Quarter 2020 Highlights Revenue of $63.5 million for the three […]
Company initiates development of CLBS119 for the repair of COVID-19 induced lung damage and expands its proprietary CD34+ cell therapy portfolio Adds ~$16 million in funding bringing current cash to ~$34 million Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. , May 07, 2020 (GLOBE NEWSWIRE) […]
– Strategic investments round out $9.2M Series B round of financing – Sajid Malhotra joins Genetesis Board of Directors MASON, Ohio, May 7, 2020 /PRNewswire/ — Genetesis Inc, a medical technology company that has developed non-invasive, biomagnetic CardioFlux™ imaging, today announced several important updates. The company has closed significant strategic investments from TDK […]
U.S. FDA Special Protocol Assessment agreement for PRECISION-AF, a single pivotal Phase 3 clinical trial of genetically targeted Gencaro PRECISION-AF trial to evaluate Gencaro as a potential treatment for prevention of atrial fibrillation in a heart failure population for which there are no FDA indicated drug therapies PRECISION-AF clinical trial […]
Top-line Results for GALACTIC-HF Expected in Q4 2020 Ended Q1 with More Than Two Years of Going Forward Cash Based on 2020 Guidance SOUTH SAN FRANCISCO, Calif., May 06, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2020. Net loss for the […]
BRISBANE, Calif., May 06, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the first quarter ended March 31, 2020. “Our team has continued to drive toward our mission, despite the extraordinary personal and professional disruptions introduced by the COVID-19 pandemic. The progress made has been […]
ANDOVER, Mass., May 06, 2020 (GLOBE NEWSWIRE) — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended March 31, 2020. “We began 2020 with strong momentum […]
Company Secures Marketing Approvals for NEXLETOL™ and NEXLIZET™ Tablets in the U.S. as well as for NILEMDO™ and NUSTENDI™ Tablets in Europe NEXLETOL™ (bempedoic acid) Tablets Commercially Available in the U.S. on March 30th NEXLIZET™ (bempedoic acid and ezetimibe) Tablets Commercially Available in the U.S. on June 4th Strong Capital […]
